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a b s t r a c t
The use of anti-TNF-α has been associated with several changes in lipid profi le, although 
some study results are confl icting. The knowledge of this fact is of great importance when 
one observes at the association between rheumatic diseases and accelerated atherogenesis. 
The aim of this analysis was search for changes in lipid profi le in anti TNF-α users in the 
population of Southern Brazil and its association with duration of use, indications, patient 
gender and type of anti-TNF. For this purpose, we studied the profi les of total cholesterol 
(TC), HDL cholesterol (HDLc), LDL cholesterol (LDLc), atherogenic index (ATI) and triglycerides 
(TGs) of 58 patients (42 with rheumatoid arthritis and 16 with spondyloarthritis) before and 
after using this drug for a median of 16.0 months. There were no changes in the levels of TC, 
HDLc, LDLc and ATI (P = NS). However, there was a signifi cant increase in TG levels (P = 0.03). 
The median difference between fi rst and second TG measurements was 16 mg/dL and this 
increase was not associated with gender, time of use, use indication or type of anti TNF-α (P 
= NS). It was concluded that the use of anti TNF-α is associated with increased values of TG.
© 2013 Elsevier Editora Ltda. All rights reserved.
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r e s u m o
O uso do anti-TNF alfa tem sido associado a várias alterações no perfi l lipídico, embora o es-
tudo dessas alterações tenha gerado resultados que ainda são confl itantes. O conhecimento 
desse fato é de grande importância quando se observa a associação entre doenças reumáti-
cas e aterogenêse acelerada. Esta pesquisa foi feita com o intuito de verifi car alterações no 
perfi l lipídico de usuários de anti-TNF-α na população do sul do Brasil e sua associação com 
tempo de uso, indicações, gênero do paciente e tipo de anti-TNF. Para tanto, analisaram-se os 
perfi s de colesterol total (TC), HDL colesterol (HDLc), LDL colesterol (LDLc), índice aterogênico 
(IAT) e triglicerídeos (TGs) de 58 pacientes (42 com artrite reumatoide e 16 com espondiloar-
trites) antes e depois do uso desse medicamento por um tempo mediano de 16,0 meses. Não 
se observaram alterações nos níveis de CT, HDLc, LDLc e IAT (P = NS). Todavia, houve um au-
mento signifi cativo nos níveis de TGs (P = 0,03). A diferença mediana dos valores de TGs entre 
primeira e segunda medidas foi de 16 mg/dL, e esse aumento não estava associado ao gênero 
do paciente, tempo de uso, indicação de uso ou tipo de anti-TNF-α (P = NS). Concluiu-se que 
o uso de anti TNF-α está associado com aumento nos valores de TGs.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
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Introduction
There is an increased cardiovascular risk in chronic infl am-
matory diseases such as rheumatic ones.1 This is evident 
in patients with rheumatoid arthritis (RA), when one ob-
serves that patients have a 1.7-fold higher chance of hav-
ing myocardial ischemia than the general population, a risk 
comparable to that shown by patients with type 2 diabetes 
mellitus.2
The knowledge that infl ammation and atherogenesis 
are closely associated has generated a new way to approach 
these patients from the therapeutic point of view, aiming 
to control the infl ammatory activity and reduce these com-
plications. Thus, the aggressive use of traditional DMARDs 
or new drugs such as biological ones has been offered as 
an attractive option.3,4 In a study of 49 patients with RA, 
in which 30 were treated satisfactorily with anti-TNF-α for 
12 months, it was observed that the thickness of the ca-
rotid intima-media in subjects who received this medica-
tion and monitored the disease was signifi cantly smaller 
than in those not receiving it.4 This effect was attributed 
to the improvement in the infl ammatory process. However, 
the anti TNF-α drugs also seem to have a direct effect on 
lipid metabolism.5
The administration of TNF-α to rodents is followed by an 
increase in hepatic synthesis of cholesterol and its blood 
concentrations, due to an increase in the activity of HMG-
CoA reductase. (5) This increase is not higher only because 
HMG-CoA activity is partially offset by the production and 
synthesis of squalene synthase (also known as farnesyl-di-
phosphate farnesyltransferase), which is the fi rst enzyme 
to act on the mevalonate pathway.5  
However, in humans and other primates, the adminis-
tration of this cytokine has not caused changes in the levels 
of total serum cholesterol (TC) and LDL-cholesterol (LDL-
c).5 Patients with cancer undergoing TNF-α infusion for 
fi ve days showed a 7% reduction in TC and 43% reduction 
in HDL-cholesterol (HDL-c).6 In addition to these changes, 
TNF-α increases levels of triglycerides (TGs) by a lipolytic 
action in adipose tissue, as well as by the increased hepatic 
synthesis of TGs, caused by an increase in the concentra-
tion of their precursors.5 This cytokine also promotes de-
creased clearance of TG-rich lipoproteins.5 
The study of the lipid profi le after administration of 
anti TNF-α in patients with spondyloarthritis (SA) and RA 
has shown confl icting fi ndings. Van Eijk et al.7 studied 92 
patients with SA and observed increase in TC, HDL-c and 
apolipoprotein A1, resulting in a better TC/HDL-c ratio. Cas-
tro et al.8 studied 15 patients with psoriatic arthritis and 
observed increased levels of TGs after 3 months of infl ix-
imab. Results of a meta-analysis9 of other 32 studies (13 of 
which were prospective) showed that inhibition of TNF-α in 
RA patients was associated with increased levels of TC and 
HDL-c, whereas LDL-c and the atherogenic index remained 
unchanged; the prolonged use resulted in increased levels 
of TGs and decreased Apo B/Apo A ratio. 
In this context, the present study aims to analyze the 
lipid profi le in the local population of patients with RA and 
spondyloarthritis (SA) treated with anti TNF-α. 
Methods
This is a retrospective study, which was approved by the 
local Research Ethics Committee. Patients were included 
when they had used anti-TNF-α drugs (infl iximab, etan-
ercept and adalimumab) for more than three months, for 
the treatment of RA and SA, older than 18 years, of both 
genders, who had a lipid profi le assessment performed im-
mediately before the use of anti-TNF-α drugs and another 
after their introduction and had not undergone changes in 
basal medication doses (including corticosteroids), or intro-
duction or withdrawal of agents with potential to alter the 
lipid profi le, except for anti TNF-α, during the observation 
period between the assessment of the two lipid profi les.
Demographic data, as well as data on time of use and 
indication of the drug, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), TC, HDL-c, LDL-c and TG 
levels were collected and the atherogenic index (ATI = TC/
LDL-c) was calculated. In our institution the lipid profi le is 
assessed in fasting and TC, TGs, LDL-c and HDL-c are mea-
sured by enzymatic/colorimetric methods. Normal values 
were considered as TC up to 200 mg/dL, HDL-cholesterol 
levels above 40 mg/dL, LDL-cholesterol up to 110 mg/dL and 
TG up to 150 mg/dL. 
The data were collected in spreadsheets and analyzed 
using the Graph Pad Prism program, release 5.0. Student’s t 
test, Mann Whitney and Krukall Wallis tests were used for 
association studies, whereas Spearman’s test was used for 
the correlation study. The signifi cance level was set at 5%.
Results
Analyzing the medical records of 609 patients with RA and 
134 patients with SA, 125 users of anti TNF-α were identi-
fi ed. Of these, 58 patients met the requirements described 
above for data analysis and constituted the sample that 
was studied. There were 31.0% of men and 68.9% women, 
mean age 47.1 ± 12.9 years and mean disease duration of 
12.7 ± 7.4 years. The indication was RA in 72.4% (42/58) and 
SA in 27.5% (16/58); 50% (29/58) used etanercept, 6.8% (4/58) 
adalimumab and 43.1% (25/58) used infl iximab. The dura-
tion of drug use ranged from 8.1-24.6 months (median of 
16.04 months).
Prednisone was used by 70.68% (41/58) of patients, with 
a median dose of 10 mg/day; methotrexate was used by 
37.93% (22/58) of patients, lefl unomide by 29.31% (17/58); 
antimalarial drugs by 25.86% (15/58); sulfasalazine by 8.62% 
(5/58) and azathioprine by 3.44% (2/58) of patients.
The lipid profi le values obtained before and after TNF-α 
use can be seen in Table 1, which showed there was a sig-
nifi cant increase in TG values  after the use of these drugs.
The median variability in TG values (ΔTGs) was 16.0 mg/
dL. When analyzing this variation in relation to patient 
gender, type of anti TNF-α and disease indication, no differ-
ences were found, as seen in Table 2.
When analyzing the variability in TG values (ΔTGs) in 
relation to time of use, there was no correlation between 
these two variables (R = 0.008, 95%CI: -0.25 to +0.27, P = 0.94).
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Discussion
The effect of anti-TNF-α on the lipid profi le of its users is con-
troversial. In the present study, there were no changes in the 
profi le of TC, HDL-c, LDL-c or atherogenic index. In contradic-
tion to what would be expected considering the known mecha-
nisms of TNF-α effect on the lipid profi le, there was an increase 
in TGs. These fi ndings are in agreement with those by Castro et 
al.,8 Stern et al.,10 Kiortsis et al.11 and Tam et al.12 However, in at 
least two other studies13-14 there were no signifi cant changes in 
TG levels, while in two others15,16 found a decrease in TG levels.
Although the contribution of hypertriglyceridemia to ath-
erosclerotic disease has not been much appreciated in the 
past, it is known today that the increase in TG levels is inde-
pendently associated with cardiovascular risk, particularly the 
coronary type.17 However, to date, a causal link between these 
two variables has not been established, as the accumulation of 
TGs in atherosclerotic plaques is very small when compared to 
the accumulation of cholesterol.17 
Notwithstanding these concerns, a study carried out in 2007 
with 14,000 young men showed that hypertriglyceridemia was 
associated with increased coronary risk and that the increase 
Table 2 – Variability of levels of triglycerides (ΔTG) 
according to gender, indication for use and type of anti 
TNF-ɲ.
Gender Median 'TG in males 
of 10.0 mg/dL
P = 0.46
Median 'TG in  females  
of  21.5 mg/dL
Type of anti-TNF-α Median 'TG of etanercept  
of  21 mg/dL 
P = 0.71
Median 'TG of infl iximab 
of 19.5 mg/dL
Median 'TG of adalimumab 
of 4.5  mg/dL
Indication for use Median 'TG in rheumatoid  
arthritis of 20.25  mg/dL
P = 0.34
Median 'TG in spondyloarthritis 
of 10.5 mg/dL
Table 1 – Variation in lipid profi le values  and 
infl ammatory activity before and after the use of anti-
TNF-ɲ.
Before After P
Total cholesterol 
(mg/dL)
Mean of 
179.1 ± 38.12
Mean of 
177.4 ± 32.3
1.00
HDL cholesterol 
(mg/dL)
Mean of 
55.7 ± 16.5
Mean of 
55.4 ± 14.86
0.90
LDL cholesterol 
(mg/dL) 
Median 
of 102.4
Median 
of 95.8
0.31
Atherogenic index Median 
of 3.1
Median 
of 3.2
0.96
Triglycerides 
(mg/dL)
Median 
of 90.5
Median 
of 105.0
0.03
ESR (mm /1st hour) Median 
of 28.5
Median 
of 19.0
0.02
C-reactive protein 
(mg/dL)
Median 
of 1.35
Median 
of 0.12
0.03
ESR, erythrocyte sedimentation rate.
in TG levels between two measurements increased this risk.18 
Furthermore, it is known that hypertriglyceridemia is associ-
ated with glucose intolerance and insulin resistance.17 
No differences could be demonstrated between the sev-
eral forms of TNF-α inhibition in the present study regarding 
TG levels. Garcês et al.19 studied the effects of etanercept and 
infl iximab on the lipid profi le in a sample of patients with RA, 
psoriatic arthritis and SA, observed differences between the 
two agents, the fi rst being associated with increases in TC 
and LDL-c and the second with increased HDL-c levels. These 
authors attributed a class-specifi c effect to these drugs, sec-
ondary to the different capabilities of blocking lymphotoxin-α, 
which would have a pro-atherogenic effect. Other studied vari-
ables, such as gender and time of use, did not infl uence the 
changes observed in the present study. Interestingly, Jacobsson 
et al.20 found that the use of anti-TNF-α improves survival in 
women, but not in men with RA.
It is quite likely that the cardiovascular protective factor of 
anti-TNF was not due to changes in the lipid profi les of pa-
tients, given the pleomorphic actions of TNF-α in the cardio-
vascular system. However, further studies are necessary to 
clarify the importance of these metabolic changes, especially 
in cases of long-term use of this drug group.
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